Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide

Ying Wu,[†] Lei Wang,[†] Yahui Huang,[†] Shuqiang Chen,[†] Shanchao Wu,[†] Guoqiang Dong,^{*,†} and Chunquan Sheng^{*,†,‡,§}

[†]Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

[‡]School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China

Supporting Information

ABSTRACT: Chidamide is a histone deacetylase (HDAC) inhibitor that is currently used to treat cutaneous T-cell lymphoma in clinic. Herein nicotinamide phosphoribosyltransferase (NAMPT) was identified to be a new target of chidamide on the basis of the pharmacophore analysis, molecular docking, biological assays, inhibitor design, and structure–activity relationship study. The polypharmacology of chidamide will provide important information for better understanding its antitumor mechanism. Also, design of dual NAMPT/HDAC inhibitors may serve as an effective strategy to develop novel antitumor agents.

KEYWORDS: Chidamide, histone deacetylase, nicotinamide phosphoribosyltransferase, dual inhibitors

The balance between acetylation and deacetylation of histone plays an essential role in maintaining cell homeostasis.¹ These two processes are regulated by histone acetyltransferase (HAT) and histone deacetylase (HDAC) which increases and decreases gene transcription, respectively.² It has been reported that HDAC is overexpressed in various tumor cells.^{3,4} HDAC inhibitors (Figure 1) can decrease the acetylation level to modify the gene expression and induce death of cancer cells.⁵ HDAC inhibitors (e.g., vorinostat, romidepsin, belinostat, and panobinostat) have been widely used in the clinic for the treatment of cutaneous T-cell lymphoma and multiple myeloma.^{6–8} Chidamide (**1**) is a benzamide HDAC inhibitor, which was marketed in China for the treatment of cutaneous T-cell lymphoma in 2015.⁹ Chidamide showed good inhibitory activity against class I (HDAC1–3) and class IIb HDACs (HDAC10), whereas it was poorly effective toward other class I, IIa, and IV HDAC isoforms.¹⁰ Although its antitumor potency and antitumor mechanism have been widely investigated,^{11–14} the research for target profiling of chidamide is still rare, which limits deeper understanding its antitumor mechanism.

Nicotinamide adenine dinucleotide (NAD⁺) plays an essential role in cellular physiological processes.¹⁵ There are four synthetic routes of NAD⁺, including the *de novo* pathway

synthesized from tryptophan (Trp), the alternative salvage pathway synthesized from nicotinic acid (NA) or nicotinamide ribose (NR), and the primary salvage pathway synthesized from nicotinamide (NAM). In mammalian cells, NAD⁺ relies on the primary salvage pathway using NAM as the precursor, in which nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme¹⁶ (Figure 1A). Recently, NAMPT is recognized as a promising target for the development of novel antitumor agents. Although two NAMPT inhibitors (FK866 and CHS828) have been progressed into clinical trials for treatment of cutaneous T-cell lymphoma and metastatic melanoma.¹⁷ However, further drug development was hampered due to significant side effects, which inspired the discovery of novel NAMPT inhibitors. Previously, we identified a series of new NAMPT inhibitors through high-throughput screening.^{18–20} Moreover, novel NAMPT/HDAC dual inhibitors were rationally designed on the basis of the synergistic effects between NAMPT and HDAC, which showed excellent *in vitro* and *in vivo* antitumor efficacy toward human colon cancer cell HCT116.²¹ Herein NAMPT was

Received: September 4, 2019

Accepted: December 13, 2019

Published: December 13, 2019

Figure 1. (A) Pathway of NAD⁺ biosynthesis. (B) Pharmacophore of HDAC inhibitors. (C) Pharmacophore of NAMPT inhibitors.

proven to be a new target of chidamide by pharmacophore analysis, molecular docking, inhibitor design, and biological assays, which provided new insights for the antitumor mechanism of chidamide and important information for new antitumor drug development.

The pharmacophore of HDAC inhibitors consists of three parts (Figure 1B): cap, linker, and zinc binding region (ZBG, hydroxamic acid or *o*-phenylenediamine).²² Similar to HDAC inhibitors, the pharmacophore of NAMPT inhibitors also includes cap, linker, and hydrophobic tails (Figure 1C). For chidamide, its (*E*)-3-(pyridin-3-yl)acrylamide ZBG could be regarded as a bioisostere of the hydrophobic tail in NAMPT inhibitors. Thus, we envisioned that chidamide might be a NAMPT inhibitor.

To validate the hypothesis, molecular docking was initially carried out to investigate whether chidamide shares a similar binding mode to NAMPT inhibitors. Chidamide was docked into the active site of NAMPT (PDB code 2GVJ)²³ using docking software Gold.²⁴ The results showed that chidamide bound to the same pocket of FK866 in the active site of NAMPT (Figure 2). As shown in Figure 2A, the pyridyl group of chidamide formed face to face π - π interactions with TYR18, PHE193, and ARG311, respectively, which were similar to that of FK866. The carbonyl oxygen and nitrogen atom of the pyridyl amide group formed two hydrogen bonds with SER275 and ASP219, respectively, while FK866 only formed a hydrogen bond with SER275. The results suggested that chidamide could bind to the active site of NAMPT. Thus, the inhibitory activity of chidamide against human recombinant NAMPT was tested using the fluorometric assay described in our previous studies.¹⁹ As shown in Table 1, chidamide was proven to be a NAMPT inhibitor with an IC₅₀ value of 2.1 μ M.

Cellular thermal shift assay (CETSA)²¹ was further performed to investigate whether NAMPT is the direct binding target of chidamide in HCT116 cells using FK866 as the positive control. The results indicated that the NAMPT expression level of cells treated with chidamide was more stable compared with the control, indicating a good binding

Figure 2. Predicted binding mode of chidamide in the active site of NAMPT (PDB code 2GVJ). (A) Predicted binding pose of chidamide in the active region of NAMPT. Hydrogen bonds (yellow) are represented with dash lines. The figure was generated using PyMol (<http://www.Pymol.org/>). (B) Superimposition of FK866 (green) and chidamide (purple) in the active region of NAMPT. The figure was generated using PyMol (<http://www.Pymol.org/>).

affinity between the chidamide and NAMPT protein (Figure 3).

The decrease in NAD⁺ level is a classic feature after inhibition of NAMPT activity.²¹ Therefore, we measured the NAD⁺ variation qualitatively compared with the control group. As shown in Figure 4A, chidamide effectively decreased the cellular NAD⁺ level after incubation with human HCT116 cells for 24 h.

The addition of NA could activate the alternative rescue pathway to synthesize NAD⁺. Furthermore, the addition of the downstream product NMN could skip the exertion of activity of NAMPT to obtain NAD⁺. Herein, rescue studies²⁵ showed that addition of NA (4 μ M) or NMN (10 μ M) could significantly rescue cells from treatment with chidamide in HCT116 cells and human leukemia cells including K562, HL60, and HEL (Figure 4B–E), further confirming that NAMPT is a target of chidamide.

To investigate the role of NAMPT in exerting the antitumor activity of chidamide, four chidamide analogs 7a–d (Scheme 1) were designed as the control molecules by removing the pharmacophores of HDAC (*o*-phenylenediamine) or NAMPT ((*E*)-3-(pyridin-3-yl)acrylamide) inhibitors. Enzyme inhibition and in vitro antitumor activity assay (Table 1) showed that compounds 7a and 7b without the pharmacophore of NAMPT inhibitors lost NAMPT inhibitory activity. Interestingly, their HDAC1 inhibitory activities were improved, while HDAC2 and HDAC3 inhibitory activities were comparable to chidamide (Table 1). For the antitumor activity, they retained good potency against the K562 cell line, whereas the growth inhibitory activity against HCT116, HL60, and HEL cell lines was decreased. Similarly, after the removal of pharmacophore of HDAC inhibitors, compounds 7c and 7d lost HDAC inhibitory activity but retained the NAMPT inhibitory activity. However, their antitumor activities were significantly de-

Table 1. Enzyme Inhibition and in Vitro Antitumor Activity of Target Compounds (IC_{50} , μM)

	compound				
	chidamide	7a	7b	7c	7d
NAMPT	2.1 $\pm$ 0.10	>100	>100	2.5 $\pm$ 0.20	3.9 $\pm$ 1.1
HDAC1	0.13 $\pm$ 0.0020	0.026 $\pm$ 0.004	0.033 $\pm$ 0.0070	>100	>100
HDAC2	0.11 $\pm$ 0.0004	0.14 $\pm$ 0.0016	0.15 $\pm$ 0.0015	>100	>100
HDAC3	0.33 $\pm$ 0.028	0.36 $\pm$ 0.018	0.32 $\pm$ 0.0064	>100	>100
HCT116	0.34 $\pm$ 0.064	2.6 $\pm$ 0.45	2.4 $\pm$ 0.87	>20	>20
K562	0.32 $\pm$ 0.063	0.38 $\pm$ 0.17	0.14 $\pm$ 0.08	0.70 $\pm$ 0.16	4.1 $\pm$ 1.2
HL60	0.0022 $\pm$ 0.0010	1.5 $\pm$ 0.56	0.37 $\pm$ 0.042	11 $\pm$ 1.2	8.4 $\pm$ 2.0
HEL	0.013 $\pm$ 0.0071	1.5 $\pm$ 0.55	1.2 $\pm$ 0.52	5.0 $\pm$ 0.67	4.7 $\pm$ 0.65
HCT116-siRNA	>20	9.7 $\pm$ 1.9	6.1 $\pm$ 0.31	>20	>20
K562-siRNA	2.4 $\pm$ 0.26	0.40 $\pm$ 0.12	0.27 $\pm$ 0.06	>20	>20
HL60-siRNA	3.2 $\pm$ 0.40	0.89 $\pm$ 0.080	0.48 $\pm$ 0.03	>20	>20
HEL-siRNA	1.8 $\pm$ 0.23	2.3 $\pm$ 0.090	1.4 $\pm$ 0.21	>20	>20

Figure 3. Binding of chidamide with NAMPT using CETSA. (A) Western blot of CETSA for NAMPT with FK866 (10 μM) and chidamide (10 μM) in HCT116 cells after the treatment for 2 h. (B) CETSA melt curves in HCT116 cells for NAMPT with FK866 and chidamide (at 10 μM).

creased. Compounds **7a–d** and chidamide were also assayed for cytotoxicity against cancer cells deficient in NAMPT using siRNA.²⁶ The results indicated that NAMPT inhibitors chidamide, **7a**, and **7b** showed decreased inhibitory activity in NAMPT-deficient cells, further confirming that NAMPT is a target of chidamide. The detailed contribution of HDAC1–3 and NAMPT to the antitumor activity of chidamide still remains to be further explored.

In summary, NAMPT was identified to be a new target of chidamide on the basis of the similarity of pharmacophore between HDAC and NAMPT inhibitors. Chidamide had low micromolar inhibitory activity toward NAMPT and significantly decreased cellular NAD^+ level, which shares a similar binding mode to NAMPT inhibitor FK866. The results are helpful for better understanding of antitumor mechanism of chidamide. The modification of chidamide by removal of HDAC pharmacophore and NAMPT pharmacophore significantly decreased its antitumor activity, indicating that dual inhibition of HDAC and NAMPT might lead to improved antitumor activity. In our previous studies, the balanced inhibitory activity against both targets was found to be important for the antitumor activity.²¹ Considering the

Figure 4. (A) Relative NAD^+ level in HCT116 cells treated with chidamide at different concentrations for 24 h. Rescue studies with the addition of NA (4 μM) or NMN (10 μM) in HCT116 cells (B), K562 cells (C), HL60 cells (D), and HEL cells (E).

Scheme 1. Chemical Synthesis of Target Compounds^a

^aReagents and conditions: (a) CH_3OH , H_2SO_4 , reflux, 6 h, yield 92%; (b) (*E*)-3-(pyridin-4-yl)acrylic acid or (*E*)-3-(pyridin-3-yl)acrylic acid or cinnamic acid, HATU, DIPEA, DMF, rt, 2 h, yield 85–93%; (c) LiOH, THF/MeOH/ H_2O , rt, 4 h, yield 80–92%; (d) different substituted anilines, HATU, DIPEA, DMF, rt, 2 h, yield 76–88%.

synergistic effects of HDAC and NAMPT, HDAC/NAMPT dual inhibitors might be a promising strategy for the development of novel antitumor agents.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00407>.

Chemical synthesis and structural characterization of the target compounds; protocols of biological assays (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*G.D.: phone/fax, +86 21 81871242; e-mail, dgq-81@163.com.

*C.S.: phone/fax, +86 21 81871239; e-mail, shengcq@smmu.edu.cn.

ORCID

Chunquan Sheng: 0000-0001-9489-804X

Author Contributions

G.D. and C.S. designed the experiments and revised the manuscript. Y.W. synthesized chidamide analogs and carried out the biological experiments. L.W., Y.H., S.C., and S.W. assisted in the biological experiments and preparing of the manuscript. All authors discussed the results and commented on the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Key R&D Program of China (Grant 2017YFA0506000 to C.S.), National Natural Science Foundation of China (Grant 81725020 to C.S. and Grant 81872742 to G.D.), and the Innovation Program of Shanghai Municipal Education Commission (Grant 2019-01-07-00-07-E00073 to C.S.).

Notes

The authors declare no competing financial interest.

■ ABBREVIATIONS

NAMPT, nicotinamide phosphoribosyltransferase; HDAC, histone deacetylase; NAD⁺, nicotinamide adenine dinucleotide; NRK, nicotinamide ribose kinase; NAPRT, nicotinic acid phosphoribosyltransferase; Trp, tryptophan; NAM, nicotinamide; NMN, nicotinamide mononucleotide; ZBG, zinc-binding group; CETSA, cellular thermal shift assay; NA, nicotinic acid

■ REFERENCES

- (1) Sun, W.; Lv, S.; Li, H.; Cui, W.; Wang, L. Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors. *Genes* **2018**, *9* (12), 633.
- (2) Guo, P.; Chen, W.; Li, H.; Li, M.; Li, L. The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications. *Pathol. Oncol. Res.* **2018**, *24* (4), 807–813.
- (3) Spartalis, E.; Athanasiadis, D. I.; Chrysikos, D.; Spartalis, M.; Boutzios, G.; Schizas, D.; Gampis, N.; Damaskos, C.; Paschou, S. A.; Ioannidis, A.; Tsourouflis, G.; Dimitroulis, D.; Nikiteas, N. I. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma. *Anticancer Res.* **2019**, *39* (3), 1119–1127.
- (4) Tsilimigras, D. I.; Ntanasis-Stathopoulos, I.; Moris, D.; Spartalis, E.; Pawlik, T. M. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. *Surgical oncology* **2018**, *27* (4), 611–618.

- (5) Haery, L.; Thompson, R. C.; Gilmore, T. D. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. *Genes Cancer* **2015**, *6* (5–6), 184–213.
- (6) Ververis, K.; Hiong, A.; Karagiannis, T. C.; Licciardi, P. V. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. *Biologics: targets & therapy* **2013**, *7*, 47–60.
- (7) Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. *Oncologist* **2007**, *12* (10), 1247–1252.
- (8) Bailey, H.; Stenehjem, D. D.; Sharma, S. Panobinostat for the treatment of multiple myeloma: the evidence to date. *J. Blood Med.* **2015**, *6*, 269–76.
- (9) Moskowitz, A. J.; Horwitz, S. M. Targeting histone deacetylases in T-cell lymphoma. *Leuk. Lymphoma* **2017**, *58* (6), 1306–1319.
- (10) Ning, Z. Q.; Li, Z. B.; Newman, M. J.; Shan, S.; Wang, X. H.; Pan, D. S.; Zhang, J.; Dong, M.; Du, X.; Lu, X. P. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. *Cancer Chemother. Pharmacol.* **2012**, *69* (4), 901–909.
- (11) Chan, T. S.; Tse, E.; Kwong, Y. L. Chidamide in the treatment of peripheral T-cell lymphoma. *OncoTargets Ther.* **2017**, *10*, 347–352.
- (12) Jin, J.; Zheng, C.; Wu, S. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review. *Medicine (Philadelphia, PA, U. S.)* **2018**, *97* (2), e9611.
- (13) Lu, X.; Ning, Z.; Li, Z.; Cao, H.; Wang, X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. *Intractable Rare Dis. Res.* **2016**, *5* (3), 185–191.
- (14) Luo, S.; Ma, K.; Zhu, H.; Wang, S.; Liu, M.; Zhang, W.; Liang, S.; Xu, N. Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells. *Oncol. Lett.* **2017**, *14* (6), 6869–6875.
- (15) Sauve, A. A. NAD⁺ and vitamin B3: from metabolism to therapies. *J. Pharmacol. Exp. Ther.* **2008**, *324* (3), 883–893.
- (16) Grolla, A. A.; Travelli, C.; Genazzani, A. A.; Sethi, J. K. Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabolite. *British journal of pharmacology* **2016**, *173* (14), 2182–2194.
- (17) Chen, H.; Wang, S.; Zhang, H.; Nice, E. C.; Huang, C. Nicotinamide phosphoribosyltransferase (Namt) in carcinogenesis: new clinical opportunities. *Expert Rev. Anticancer Ther.* **2016**, *16* (8), 827–838.
- (18) Wang, X.; Xu, T. Y.; Liu, X. Z.; Zhang, S. L.; Wang, P.; Li, Z. Y.; Guan, Y. F.; Wang, S. N.; Dong, G. Q.; Zhuo, S.; Le, Y. Y.; Sheng, C. Q.; Miao, C. Y. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT. *Sci. Rep.* **2015**, *5*, 12657.
- (19) Xu, T. Y.; Zhang, S. L.; Dong, G. Q.; Liu, X. Z.; Wang, X.; Lv, X. Q.; Qian, Q. J.; Zhang, R. Y.; Sheng, C. Q.; Miao, C. Y. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. *Sci. Rep.* **2015**, *5*, 10043.
- (20) Chen, W.; Dong, G.; He, S.; Xu, T.; Wang, X.; Liu, N.; Zhang, W.; Miao, C.; Sheng, C. Identification of benzothiofene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase. *Bioorg. Med. Chem. Lett.* **2016**, *26* (3), 765–768.
- (21) Dong, G.; Chen, W.; Wang, X.; Yang, X.; Xu, T.; Wang, P.; Zhang, W.; Rao, Y.; Miao, C.; Sheng, C. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. *J. Med. Chem.* **2017**, *60* (19), 7965–7983.
- (22) Li, Y.; Wang, F.; Chen, X.; Wang, J.; Zhao, Y.; Li, Y.; He, B. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups. *Curr. Top. Med. Chem.* **2019**, *19* (3), 223–241.
- (23) Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. *Nat. Struct. Mol. Biol.* **2006**, *13* (7), 582–588.

(24) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. *J. Mol. Biol.* **1997**, *267* (3), 727–748.

(25) O'Brien, T.; Oeh, J.; Xiao, Y.; Liang, X.; Vanderbilt, A.; Qin, A.; Yang, L.; Lee, L. B.; Ly, J.; Cosino, E.; LaCap, J. A.; Ogasawara, A.; Williams, S.; Nannini, M.; Liederer, B. M.; Jackson, P.; Dragovich, P. S.; Sampath, D. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models. *Neoplasia (New York, N.Y.)* **2013**, *15* (12), 1314–1329.

(26) Lv, X.; Zhang, L.; Zhu, Y.; Said, H. M.; Shi, J.; Xu, G. Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer. *J. Cancer* **2015**, *6* (9), 849–858.